
Novo Nordisk has withdrawn a press statement on Tresiba, which was issued on Sep. 19, 2019, after the Danish Maritime and Commercial High Court has ruled that it contained misleading marketing, which Novo Nordisk announces on Monday.
Last year's press announcement stated that Novo expected to present improvements in the average blood sugar level and in cases with low blood sugar – known as hypoglycemia – in the company's insulin product Tresiba, compared with the competing drug Toujeo from French pharmaceutical firm Sanofi.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app